Ginkgo Bioworks Holdings, Inc.
DNA
$6.86
$0.172.47%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -23.84% | -56.39% | -11.75% | 27.34% | 26.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -23.84% | -56.39% | -11.75% | 27.34% | 26.16% |
| Cost of Revenue | -24.12% | 6.66% | 8.02% | 30.92% | 45.55% |
| Gross Profit | -23.75% | -66.21% | -18.13% | 26.20% | 21.61% |
| SG&A Expenses | -11.49% | -14.03% | -34.71% | -30.22% | -20.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.03% | -10.04% | -47.97% | -38.87% | -26.89% |
| Operating Income | 25.59% | -68.93% | 60.85% | 52.98% | 38.86% |
| Income Before Tax | 24.54% | -42.23% | 72.08% | 45.22% | 49.10% |
| Income Tax Expenses | -97.85% | 100.27% | -248.95% | 183.87% | -64.14% |
| Earnings from Continuing Operations | 24.91% | -43.18% | 72.24% | 45.18% | 49.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.91% | -43.18% | 72.24% | 45.18% | 49.20% |
| EBIT | 25.59% | -68.93% | 60.85% | 52.98% | 38.86% |
| EBITDA | 26.57% | -82.09% | 67.25% | 58.62% | 41.06% |
| EPS Basic | 29.20% | -34.44% | 74.00% | 49.35% | 53.33% |
| Normalized Basic EPS | 31.90% | -94.60% | 63.46% | 53.68% | 41.68% |
| EPS Diluted | 28.97% | -34.39% | 74.00% | 49.38% | 53.37% |
| Normalized Diluted EPS | 31.90% | -94.60% | 63.46% | 53.66% | 41.64% |
| Average Basic Shares Outstanding | 6.07% | 6.50% | 6.79% | 8.24% | 8.84% |
| Average Diluted Shares Outstanding | 6.07% | 6.48% | 6.78% | 8.19% | 8.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |